Markets need more proof of potential; guidance upgrade apparently won't cut it
23/10/25 -"The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again the key performance driver, whereas Diagnostics ..."
Pages
69
Language
English
Published on
23/10/25
You may also be interested by these reports :
24/10/25
The Q3 operating profitability came in considerably ahead of the street’s estimates, though sales met expectations. The performance was driven by ...
23/10/25
The Q3 sales missed expectations by a small margin; however, the management upgraded its 2025 earnings outlook. The Pharmaceuticals segment was again ...
23/10/25
Lonza’s strong Q3 commentary reaffirmed its commitment to meeting the 2025 guidance, boosting investor sentiment. While operational figures were not ...
22/10/25
Ipsen’s Q3 sales surpassed expectations, showing robust growth across all segments. Consequently, the 2025 guidance has been revised upwards. The ...